Gustafson, William Clay <br/><br/>
Drugging MYCN through an allosteric transition in Aurora kinase A.  [electronic resource] 

 -  Cancer cell  Sep 2014 
 - 414-427 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1878-3686 
<br/><br/><label>Standard No.: </label>10.1016/j.ccr.2014.07.015  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Allosteric Regulation<br/>Animals<br/>Antineoplastic Agents--chemistry<br/>Area Under Curve<br/>Aurora Kinase A--antagonists & inhibitors<br/>Catalytic Domain<br/>Cell Line, Tumor<br/>Cell Survival--drug effects<br/>Crystallography, X-Ray<br/>Humans<br/>Mice<br/>Mice, Inbred NOD<br/>Mice, Nude<br/>Mice, SCID<br/>Models, Molecular<br/>N-Myc Proto-Oncogene Protein<br/>Neuroblastoma--drug therapy<br/>Nuclear Proteins--chemistry<br/>Oncogene Proteins--chemistry<br/>Phenylurea Compounds--chemistry<br/>Phosphorylation<br/>Protein Processing, Post-Translational<br/>Protein Structure, Secondary<br/>Proteolysis<br/>Pyrimidines--chemistry<br/>S Phase Cell Cycle Checkpoints--drug effects<br/>Structure-Activity Relationship<br/>Tumor Burden--drug effects<br/>Xenograft Model Antitumor Assays